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Abstract: The global prevalence and impact of diabetes has increased dramatically, particularly 
in sub-Saharan Africa. This region faces unique challenges in combating the disease including 
lack of funding for noncommunicable diseases, lack of availability of studies and guidelines 
specific to the population, lack of availability of medications, differences in urban and rural 
patients, and inequity between public and private sector health care. Because of these challenges, 
diabetes has a greater impact on morbidity and mortality related to the disease in sub-Saharan 
Africa than any other region in the world. In order to address these unacceptably poor trends, 
contextualized strategies for the prevention, identification, management, and financing of diabe-
tes care within this population must be developed. This narrative review provides insights into 
the policy landscape, epidemiology, pathophysiology, care protocols, medication availability, 
and health care systems to give readers a comprehensive summary of many factors in these 
domains as they pertain to diabetes in sub-Saharan Africa. In addition to providing a review of 
the current evidence available in these domains, potential solutions to address the major gaps in 
care will be proposed to reverse the negative trends seen with diabetes in sub-Saharan Africa. 
Keywords: outcomes, protocols, medication access, pathophysiology, epidemiology, health 
care systems
Introduction
Diabetes is a disease that wreaks havoc when health care systems are not aligned and 
consistently functioning.1 This is clearly illustrated by the suboptimal results seen in indi-
vidual patients and patient cohorts in the relatively few studies available from sub-Saharan 
Africa.2–4 With inadequate spending to bolster health care systems to manage chronic 
diseases, there have been only minimal population-level gains in chronic disease health 
outcomes, especially with regard to diabetes.2,5 To improve care for diabetes populations 
in sub-Saharan Africa, a comprehensive evaluation of the policy landscape, epidemiology, 
pathophysiology, care protocols, medication availability, and health care systems must be 
considered (Figure 1). With the dramatic differences between care in high-income countries 
(HICs) versus low- and middle-income countries (LMIC), rural versus urban settings, and 
private versus public sector systems, special considerations for each need to be made to 
maximize health care benefits. This review briefly touches upon these key differences and 
also provides overarching suggestions to sustainably address the identified gaps in care. 
Methods
This nonsystematic, narrative review utilizes the limited amount of currently avail-
able primary information from a literature search by using PubMed search criteria 
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including “diabetes and sub-Saharan Africa” and other avail-
able information from Internet searches of respected and 
reputable institutions including the International Diabetes 
Federation (IDF), the World Health Organization (WHO), 
the World Diabetes Foundation, governmental institutions, 
and other institutions as cited. Where data and information 
are unavailable, the authors have noted a lack of available 
information and provided informed opinions and accounts 
from personal experience from implementing diabetes care 
over the past decade in Western Kenya. This narrative method 
has brought available information into a comprehensive 
assessment of the gaps and barriers that hinder progress in 
diabetes care in sub-Saharan Africa and identifies potential 
pathways to progress.
Policy
Funding
Although most policy initiatives continue to focus on the 
growing burden of diabetes in HICs, it is important to note 
that 77% of patients with diabetes reside in LMICs.2,5 The 
importance of this rapid escalation of diabetes, especially 
in sub-Saharan Africa, cannot be overstated as it threatens 
to destabilize already fragile economies still reeling from 
infectious disease epidemics, including ebola, human 
immunodeficiency virus (HIV), tuberculosis (TB), and 
malaria.6–9 Despite the disproportionate burden of diabetes 
and other noncommunicable diseases (NCDs) in LMICs, 
external and internal funding for health care needs continues 
to focus on communicable diseases while neglecting the 
needs of the large populations experiencing excess morbid-
ity and mortality from NCDs. For example, in 2010, the 
United States committed only $10.8 million (0.14%) of its 
$8 billion in global health funding to NCDs.10 This trend 
of limited funding for NCDs is further illustrated by the 
statistics on the investments made by the US government in 
the 49 priority LMICs that it provides the highest amount of 
global health investment to. In terms of disability-adjusted 
life years (DALYs) from 2010, the US government spent 
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Figure 1 Current gaps in diabetes care in sub-Saharan Africa and potential pathways to progress. 
Abbreviations: HIV, human immunodeficiency virus; TB, tuberculosis; NCD, noncommunicable disease; SSA, sub-Saharan Africa. 
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$44.17 for each DALY lost to HIV/AIDS, $4.21 per DALY 
lost to malaria, $1.82 per DALY lost to TB, but only $0.02 
per DALY lost to NCDs.10 These disturbing trends of global 
neglect toward NCDs continue despite the commitments 
and statements made during the high-level meeting on 
NCDs at the United Nations in 2011.11 Although several 
action plans have been developed, the initial investments 
required to make them a reality in sub-Saharan Africa are 
yet to be realized.10,11
The lack of global commitment is further complicated 
by the relatively limited in-country funding that sub-Saharan 
African countries dedicate to health compared with the rest 
of the world. In 2014, sub-Saharan African countries spent 
5.5% of their gross domestic product (GDP) on health (pri-
vate and public sector) compared with the 12.4% that the 
Organization for Economic Cooperation and Development 
countries spend annually on health.12 Further examination of 
data from the World Bank in 2014 reveals that sub-Saharan 
African countries funding for public sector health care is 
only 42.6% of the total health care spending or 2.3% of the 
total GDP. Average per capita spending is $98 (US, 2014), 
despite the heavy reliance that populations in sub-Saharan 
Africa have on public sector health care.10,12,13 In comparison, 
public sector health care funding for the European Union, 
Latin America and Caribbean, and Middle East and North 
Africa are 7.8%, 3.7%, and 3.2% of the total GDP, respec-
tively, with per capita spending amounting to $3613, $714, 
and $433 (US, 2014), respectively.12,13
With the much lower GDP typically found in sub-Saharan 
Africa, the absolute amount of funding for the health care 
needs of all parts of this vast region continues to lag far 
behind other LMICs as seen in Figure 2.10
As a result of the existing high burden of infectious dis-
eases and NCDs, countries in sub-Saharan Africa have also 
typically prioritized communicable diseases over NCDs by 
committing ≥80% of their health budget to communicable 
diseases over the past two decades.14
Infrastructure
A more in-depth consideration of the policy and funding 
challenges amidst competing health care priorities paints 
an even bleaker picture around diabetes as the multiorgan 
impact of the disease, and high costs of prevention and 
management make it an even more challenging burden to 
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address. At the same time, while considering investments in 
diabetes care infrastructure, these investments can be viewed 
as investments in all NCDs. The crosscutting infrastructure 
required to comprehensively manage diabetes will benefit 
the entire health systems and will simultaneously address 
cardiovascular, ocular, mental health, renal, and neurological 
disorders. Manifestations and frequencies of these diabetes-
associated comorbidities in sub-Saharan Africa are discussed 
in the “Pathophysiology” section.
Prevention    
Although the immediate needs of the population already fac-
ing diabetes are dire, there exists an equally important need to 
introduce policy designed to encourage the creation of nutri-
tious food environments and avoid emerging food environ-
ments that are being flooded with obesogenic/diabetogenic 
foods (sugar sweetened beverages, highly processed foods, 
etc).5,15,16 This nutrition transition is fueling the dramatic rise 
in diabetes prevalence in urban areas that are shifting toward 
a more western, sedentary style of life. Although this nutrition 
and lifestyle transition does not seem to have reached many 
rural sub-Saharan African settings yet, the extension of this 
trend is inevitable as the economic growth of sub-Saharan 
Africa continues to increase. In addition to a nutritious food 
environment, education about healthy eating and physical 
activity needs to be implemented at all levels, targeting 
children and adults as well as urban and rural markets. To 
identify the unique prevention strategies needed for rural 
areas, contextualized, culturally adapted research needs to 
be supported to investigate the dietary patterns that may be 
increasing the risk for diabetes.
Path to progress
It is unlikely that a concerted funding effort will become 
available for NCDs, including diabetes, similar to that which 
was seen for HIV, TB, and malaria. In the face of this fund-
ing challenge, we are presented with a choice of allowing 
sub-Saharan African patients with diabetes to suffer unac-
ceptably high levels of excess morbidity and mortality as 
we wait for outside funding sources, or we can develop sus-
tainable strategies that address the policy-related issues that 
patients with diabetes in sub-Saharan Africa face. The second 
choice requires a multipronged and integrated approach, 
which includes prevention efforts focused on policy-based 
requirements for education about healthy lifestyles and 
disease prevention, creation of donor-independent health 
care systems that provide affordable access to high-quality 
diabetes services, and efforts to increase awareness among 
local governmental agencies responsible for domestic fund-
ing allocations.
Epidemiology
The prevalence of diabetes in sub-Saharan Africa, similar 
to trends being seen worldwide, is rapidly rising.2 The 
 sub-Saharan African region is expected to see the largest 
percentage increase in the incidence of diabetes of any 
region in the world. In 2015, the IDF estimated that there 
were 14.2 million people with diabetes in sub-Saharan 
Africa.2 This number is expected to increase to 34.2 mil-
lion patients by 2040.2 Prevalence is highly varied between 
countries, with prevalence ranging from a low of 0.6% 
in Benin to a high of 18.2% in Réunion, off the coast of 
Madagascar.2 There is also great variability in rural versus 
urban prevalence with urban areas facing the brunt of the 
burden. The wide variation in diabetes prevalence can be 
explained partly due to regional differences in lifestyle and 
body mass index (BMI), as well as the great variability 
in the methods and locations of studies used to generate 
these estimates.17
Current knowledge of diabetes in sub-Saharan Africa 
is based largely on epidemiological data taken during spo-
radic, predominantly convenience based community test-
ing initiatives and hospital data from patients who present 
with diabetes complications. There are few comprehensive 
surveys, and the wide variations in prevalence makes it dif-
ficult to have an accurate estimate of the impact of diabetes 
in the region.17 Type 2 diabetes is the predominant form of 
diabetes in sub-Saharan Africa, accounting for an estimated 
85%–95% of cases.18 Type 1 diabetes and atypical variants 
of diabetes, including malnutrition-related and ketosis prone 
diabetes, account for 5%–15% of cases.3,17 A majority of 
patients with diabetes in sub-Saharan Africa are undiagnosed, 
with an estimated 62.5% of cases being undiagnosed in the 
region.2 Under diagnosis can be attributed to a lack of access 
to health care facilities, poorly trained health care provid-
ers, and lack of screening. Further compounding with these 
deficiencies is the anticipated increase in incidence and sub-
sequent prevalence of diabetes that will accompany the rapid 
urbanization of sub-Saharan African populations. This will 
increase the proportion of the population who are exposed 
to the more diabetogenic sedentary lifestyle with calorie-rich 
diets typically seen with urbanization.3 This ongoing and 
projected shift in diet has resulted in populations consuming 
more calorically dense foods with increased fat and sugar 
and less fiber compared with the traditional diets of previ-
ous generations.3,19,20 This shift is further ingrained among 
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the cultural norms of the population as many  sub-Saharan 
African cultures view being overweight or obese as a symbol 
of wealth and prosperity.21,22
With shifts in the lifestyles of urban populations, type 2 
diabetes prevalence is 1.5–4 times higher in urban settings 
compared with rural settings.4 This is further complicated by 
the rapid urbanization taking place in sub-Saharan African 
populations. In 2013, 37% of the population lived in urban 
areas compared with only 10%–15% in 1950.23 By 2030, this 
number is expected to be 50%, making sub-Saharan Africa 
the fastest growing urban population in the world.23
In addition to changes in lifestyle and nutrition being 
common in sub-Saharan African populations and contribut-
ing to increases in diabetes prevalence, the likelihood of 
developing diabetes is also increased as the life expectancy 
in sub-Saharan Africa increases.24 As we continue to improve 
health care infrastructure and living conditions, there will 
be additional gains in life expectancy, which will continue 
to add to the incidence and prevalence of diabetes as the 
population ages.3 The specific projections for increased life 
expectancy vary across regions, but on average, the increase 
in life expectancy in Africa is expected to increase to 64 years 
by 2030 from 57 years in 2010.23
The number of patients with type 1 diabetes in sub-Saha-
ran Africa is low relative to the rest of the world.2 In 2013, the 
number of children with type 1 diabetes from birth to 14 years 
of age was 39,100, the lowest in sub-Saharan Africa compared 
with other regions in the world, a prevalence of ~0.009%.2 In 
comparison, the number of children from birth to 14 years 
of age with type 1 diabetes in Europe in 2013 was 129,400, 
a prevalence of ~0.16%.2 Unfortunately, patients who have 
type 1 diabetes are not expected to survive more than a year 
after initial diagnosis in most parts of sub-Saharan Africa 
which are not well equipped with health care facilities and 
services.24 This unfortunate reality combined with limited 
diagnosis and poor data collection confounds the evaluation 
of comparative prevalence as the excess mortality and low 
rates of detection faced in sub-Saharan Africa continues to 
lead to preventable early deaths for thousands of juvenile 
cases of diabetes that reduce the prevalence estimates for 
type 1 diabetes.24
Diabetes is particularly devastating in sub-Saharan Africa 
from both an economic and a health care standpoint. Diabe-
tes in sub-Saharan Africa is associated with the highest rate 
of morbidity and mortality in the world, particularly in the 
population who are able to work.2 In sub-Saharan Africa in 
2014, 76.4% of deaths attributed to diabetes were in people 
aged <60 years.2 The primary reasons for these high rates of 
morbidity and mortality are typically attributed to the late 
diagnosis and poor care that patients receive throughout the 
course of disease.
In addition, diabetes carries a twofold burden in sub-
Saharan Africa because of the increased risk of infectious 
diseases such as HIV, TB, and pneumonia.25 This is of signifi-
cant importance as the next epidemic of TB cases in LMICs 
are expected to be related to this increased prevalence of 
diabetes. Previous studies have shown that diabetes increases 
the risk of TB nearly threefold, and evidence also suggests 
that having TB may predispose individuals to developing 
diabetes.17,26 Furthermore, poor glycemic control in patients 
with diabetes has been associated with a higher risk for TB 
compared with patients with tightly controlled blood sugar.27 
Although there has been recent progress in stabilizing the 
number of new cases of TB through improvements in access 
to HIV treatment, many of these gains could be reversed if 
the numbers of people with diabetes continue to grow as 
projected.27,28 HIV and TB also contribute to the increase in 
diabetes cases seen in sub-Saharan Africa. TB infection, like 
other infections, can augment glucose tolerance in patients 
during infection, although it is unknown if this contributes 
significantly to the development of diabetes.26 HIV and the 
antiretroviral medications used to suppress its replication 
are both associated with metabolic dysfunction and changes 
in insulin sensitivity, leading to metabolic syndrome and/or 
diabetes.26,29 In addition, patients who receive antiretroviral 
therapy live longer, which increases the risk of developing 
diabetes because of the previously described risks with 
advanced age and extended exposure to medications with 
metabolic side effects.29 In addition to these traditional risk 
factors for diabetes development, there is a growing inter-
est in describing the role of chronic inflammation observed 
in HIV-infected patients in the development of diabetes as 
inflammation has been shown to be an independent risk fac-
tor for the development of diabetes. This is compounded by 
the findings that HIV-infected patients tend to have a higher 
degree of chronic inflammation than non-HIV-infected 
patients providing another potential source of risk for the 
development of diabetes.30
The preceding paragraphs describe the unique character-
istics that are driving the increase in diabetes in sub-Saharan 
Africa. Unfortunately, patients with diabetes are prone to 
high rates of microvascular complications. Microvascular 
complications, and their associated estimates, that are com-
monly seen in sub-Saharan African settings include cata-
racts (9%–16%),31 retinopathy (7%–63%),32–39 neuropathy 
(27%–66%),40,41 microalbuminuria (10%–83%),33,42 and 
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nephropathy (32%–57%).43,44 Although there is a great deal 
of variation in the quality and reliability of reporting these 
complications in different settings, these microvascular com-
plications seem to have a much higher prevalence in patients 
from sub-Saharan Africa, especially in those who have had 
a longer course of disease and poor glycemic control.17,45–47 
In contrast, patients in HICs experience relatively more 
macrovascular complications, such as cardiovascular dis-
ease, peripheral vascular disease, and stroke. In sub-Saharan 
African populations, these macrovascular complications 
are relatively rare despite a high prevalence of concomitant 
hypertension with diabetes.43,48
In addition to addressing these more commonly described 
diabetes-related complications, there needs to be a greater 
focus on addressing mental health conditions, such as depres-
sion, that often complicate care for patients with diabetes. 
Data from a rural diabetes specialty clinic in Kenya found 
that 21% of its patients reported depressive symptoms that 
were associated with worsened glycemic control compared 
with screen negative patients. Although mental health dis-
orders are often neglected in LMICs, the development of 
infrastructure for NCDs like diabetes necessitates a renewed 
focus on addressing mental health disorders to maximize 
patient outcomes.49–51
Although the available epidemiological data on compli-
cations illustrate the differences between HIC and LMIC 
populations, there has been only limited investigation on 
the epidemiology of the different variants of diabetes that 
are more frequently found among sub-Saharan Africa 
populations. As health care systems continue to mature in 
sub-Saharan Africa, specific strategies for differentiating 
these variants must be developed to enhance the epidemio-
logical understanding of these unique forms of diabetes. An 
enhanced epidemiological understanding would help to 
facilitate the development of variant-specific management 
approaches, which could address the underlying causes and 
nutritional deficits that lead to their development.
Path to progress
Health care systems must enhance the collection of data 
regarding diabetes to increase accuracy in predictions of 
changes in diabetes prevalence, complications, mortality, 
and presence of atypical variants. Through the integration 
of reliable data collection methods and efforts to increase 
access to reliable health care infrastructure, policy makers 
and health care systems will be equipped with the data and 
tracking capabilities needed to stave off the unprecedented 
projection of growth of patients afflicted by diabetes.  
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Figure 3 Differences in pathophysiological presentation of diabetes in HICs and urban setting diabetes compared with rural Sub-Saharan African diabetes.
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Pathophysiology
The pathophysiology of type 1 and type 2 diabetes in sub-
Saharan Africa, particularly type 2 diabetes and subtypes of 
type 2 diabetes, differs drastically from that of other regions. 
These differences are outlined in Figure 3.
Type 1 diabetes presentation in sub-Saharan Africa is 
generally later in life, with patients commonly being diag-
nosed in their 20s to 40s and with more severe clinical pre-
sentations during diagnosis including diabetic ketoacidosis 
(DKA), hyperosmolar non-ketotic coma, and hypoglycemia 
than the typical presentation of type 1 diabetes in Caucasian 
patients.29 The differences between sub-Saharan African 
and Caucasian patients extend far beyond the clinical pre-
sentation. Autoimmunity is well documented in Caucasian 
patients with type 1 diabetes from HICs; with prevalence of 
autoinsulin antibodies, islet cell antibodies, and glutamic 
acid decarboxylase enzyme antibodies measured from 65% 
to 80% at presentation of disease.29 Although information 
about the presence of antibodies is limited, autoimmunity 
measured in type 1 diabetes patients from Tanzania and 
South Africa revealed a prevalence of islet cell antibodies 
ranging from 8% to 11% and a prevalence of glutamic acid 
decarboxylase enzyme antibody of 44%.29 These studies 
suggest that autoimmunity based on the markers identified 
among Caucasian populations may not play as much of a 
role in diabetes in sub-Saharan Africa. Likewise, genetic 
markers, such as HLA DR3/4, which are known to confer 
susceptibility to type 1 diabetes in Caucasians, have lower 
prevalence in type 1 diabetes patients in sub-Saharan Africa 
than in European populations.3,29 These findings highlight the 
gaps in our current knowledge about the genetics of diabetes 
in sub-Saharan Africa while also illustrating the marked 
differences in the genetic and immune-mediated underpin-
nings of the disease.3,29 The disease is usually characterized 
by severe hyperglycemia with or without ketosis and is well 
managed with appropriate insulin therapy; however, patients 
with poor access to health care often do not survive the initial 
severe hyperglycemia episode because of either ketosis or 
infection.52
Recent investigation into the genetic variations in patients 
with diabetes from different parts of the world has provided 
additional insight to better understand the marked differences 
in diabetes pathophysiology between patients. Genetic varia-
tions and propensity for the development of disease have been 
investigated, and previous studies suggest that sub-Saharan 
African populations are at the highest risk for type 2 diabetes 
because of genetic factors despite the epidemiological observa-
tion that sub-Saharan Africa has relatively lower prevalence 
compared with most other regions in the world.53 When looking 
at genetic polymorphisms from patients around the world in 
the context of human migration, patients in sub-Saharan Africa 
were found to have the highest likelihood of type 2 diabetes, 
providing a plausible explanation for this increased risk as 
seen in Figure 4. This finding highlights the concern over the 
projected increase in the prevalence of diabetes as sub-Saharan 
Africa continues to rapidly urbanize and shift to a more urban-
ized lifestyle. Combining the explanation for increased genetic 
risk with an unparalleled lifestyle shift throughout sub-Saharan 
Africa could lead to increases in the number of patients with 
diabetes that surpass even the currently available projections 
of a 109% increase in prevalence over the next two decades.54
In comparative studies between white and black South 
African patients with impaired glucose tolerance, black 
patients showed a more rapid progression to type 2  diabetes.3,24 
Population mean
likelihood ratio
0.42 0.5 2.59
Figure 4 Likelihood of developing type 2 diabetes based on genetic polymorphisms. 
Notes: Adapted from Corona E, Chen R, Sikora M, et al. Analysis of the genetic basis of disease in the context of worldwide human relationships and migration. PLoS Genet. 
2013;9(5):e1003447. Copyright © 2013 Corona et al.54
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Reasons for the rapidly declining beta-cell function and more 
rapid progression of disease in sub-Saharan African patients 
are not conclusive at this time. Some hypotheses for this dif-
ference are differences in fat distribution as compared with 
other ethnicities, genetic variations among different sub-
Saharan African populations, a genetic predisposition to less 
functional beta cells in African patients, environmental causes 
(such as toxins and infection), consequences of intrauterine 
growth retardation, and malnutrition.24
Type 2 diabetes in sub-Saharan Africa presents in 
multiple subtypes. Similar to what is typically seen in 
type 2 diabetes in Western settings, insulin resistance is 
associated with a BMI ≥25, increased waist circumference, 
sedentary lifestyle, and high calorie diets, followed by a 
decrease in beta-cell function and eventual progression to 
type 2 diabetes in combination with metabolic syndromes 
associated with hypertension and dyslipidemias.3,17 This is 
seen primarily in urban settings and in patients of Asian 
descent and of mixed African and Middle Eastern heritage. 
Clinically, these patients are managed in the same way as 
type 2 diabetics in the Western settings and benefit from 
diet and exercise interventions as well as initial metformin 
therapy.3,17
Despite the positive link between obesity and diabetes 
in sub-Saharan African patients, a significant number of 
patients do not fit this traditional picture of type 2 diabetes. 
A unique subtype of type 2 diabetes, malnutrition-related 
diabetes, is manifested in patients who are normal or under-
weight (BMI ≤25) and develop the disease.24,29 This form 
of type 2 diabetes is seen primarily in rural sub-Saharan 
African patients. It is speculated that this form of the disease 
is caused by long-term malnutrition that eventually leads to 
pancreatic calcification. There is also suspicion that there 
may be a genetic link or infective process that accelerates 
the effects of malnutrition on the pancreas. Clinically, these 
patients present and are managed much differently than type 
2 diabetes patients in the Western settings. These patients 
generally present with severe hyperglycemia and generally 
without ketones present. The initial episode is corrected with 
high-dose insulin, often exceeding 2 units/kg daily, although 
some patients are responsive to normal doses of insulin (≤1 
unit/kg/day). Once the initial episode is controlled, these 
patients have variable courses. Some patients may go into 
“remission” and not require insulin for weeks to years and 
remain ketosis-resistant, whereas some continue to require 
insulin, and others respond well to oral agents in the absence 
of insulin. This varying response to therapy and lack of radiol-
ogy and laboratory data makes this form of diabetes difficult 
to distinguish from type 1 diabetes.24,29 Another subtype of 
type 2 diabetes found in the sub-Saharan African region is 
atypical African diabetes or ketosis-prone atypical diabetes. 
Typical presentation consists of polyuria, polydipsia, weight 
loss, and severe hyperglycemia with ketosis and is similar 
to the presentation of type 1 diabetes. These patients can be 
periodically managed with insulin, which can be discontin-
ued and replaced by oral hypoglycemic agents until insulin 
is again necessary for control.29,55
Path to progress
With the unique features of diabetes in sub-Saharan Africa, 
there needs to be considerable research on developing a better 
understanding of the dynamics of what seems to be a distinct 
disease process with different genotypic and phenotypic 
characteristics. These research efforts would unravel many 
of the mysteries surrounding diabetes in sub-Saharan Africa 
while simultaneously identifying contextualized manage-
ment strategies that speak to the underlying mechanisms of 
the disease.  
Care protocols
Despite many already described differences in diabetes found 
in sub-Saharan Africa, most sub-Saharan African country 
guidelines continue to rely heavily upon the guidelines used 
to govern the care of diabetes in HICs like the United States. 
This includes guidelines such as the American Diabetes Asso-
ciation (ADA) guidelines and the United Kingdom National 
Institute for Health and Clinical Excellence guidelines. The 
IDF also utilizes these guidelines to heavily inform their 
global guidelines on type 2 diabetes. With the vast majority 
of large randomized trials of diabetes enrolling participants 
from HICs, guideline committees, and task forces are all 
but required to rely on this high-quality data and extrapolate 
these findings to other populations in LMICs who do not have 
the luxury of relying on large randomized controlled trials 
incorporating their populations. 
This is illustrated by the recommendations from all three 
major guidelines that suggest that metformin should be used 
as the first-line medication for type 2 diabetes. Based on many 
landmark studies including the United Kingdom Prospective 
Diabetes (UKPDS), which have enrolled populations from 
HICs with the prototypical version of type 2 diabetes, which 
includes increased waist circumference, increased BMI, and 
dyslipidemia.56,57
In the UKPDS study, for example, the average BMI was 
27.5 kg/m2 for all patients in the “normal” weight arm of the 
trial compared with a BMI of 31.4 kg/m2 for the overweight 
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arm of the study. By today’s standards, the normal weight 
arm of the study would be considered overweight and the 
overweight arm would be considered obese.56,57 Although the 
UKPDS participants are representative of HIC populations 
and partially representative of the higher BMIs found in urban 
populations in sub-Saharan Africa, the applicability of the 
findings from this population to rural sub-Saharan Africa is 
limited considering the differences in patient characteristics.58 
For example, in a study of 525 patients with diabetes in rural 
Kenya, 74% of the population had a BMI <30 despite being 
diagnosed with diabetes.59 With the marked differences in 
anthropometric characteristics, it is difficult to apply findings 
from studies like UKPDS to populations that do not have 
the same features. Furthermore, <10% of any of the study 
arms from UKPDS comprised of patients of Afro-Caribbean 
descent further limiting the ability to extrapolate these land-
mark findings to populations in sub-Saharan Africa.57 
Despite the lack of randomized controlled trial evidence 
to guide care in sub-Saharan Africa, clinicians and research-
ers from Partners in Health have developed contextualized 
guidelines that reflect the unique challenges commonly 
encountered while managing patients with diabetes in sub-
Saharan Africa.60 Their overarching recommendations for 
the management of type 2 diabetes in LMICs can be seen in 
Figure 5. These guidelines provide much needed guidance 
to LMIC clinicians trying to manage the higher percentage 
of patients with normal or underweight diabetes. Instead of 
applying the typical approach of lifestyle modification fol-
lowed by metformin, this guideline provides a much more 
contextualized approach that tailors treatment according to 
the BMI, limited selection of medications typically avail-
able, and blood glucose measurements that are available in 
facilities in LMICs.60  
In contrast, the ADA guidelines illustrate various 
pharmacological approaches utilized in most HICs with 
an emphasis on metformin use for almost all patients.61 
Although these guidelines are supported by large, random-
ized control trials, the applicability of these recommenda-
tions to sub-Saharan African populations is limited, as many 
of these medications are unavailable and cost prohibitive 
for most patients in the region. The ADA guidelines also 
fail to take into consideration the unique anthropometric 
characteristics of sub-Saharan Africa populations and more 
active lifestyle of rural sub-Saharan Africa populations.61
Path to progress
Many distinct features of diabetes in sub-Saharan Africa 
help to expose the immense need for care protocols that 
speak directly to various challenges that sub-Saharan Africa 
patients and clinicians face while trying to follow the 
guidelines developed for an entirely different population. 
As the number of patients with diabetes in sub-Saharan 
Africa increases continuously, the consumer demand for 
effective treatments will necessitate the identification of 
contextualized management strategies that help prevent 
the excess morbidity and mortality that patients are cur-
rently facing.
Medication availability
Increasing access to essential medicines is one of the targets 
of the Millennium Development Goals (MDGs).63 However, 
from a policy perspective, access to essential medicines has 
been neglected as a priority target for the MDGs, as evi-
denced by the fact that this target is missing from most of 
the MDGs reports.64 As a result, large disparities continue 
to exist in access to essential medicines between HICs and 
LMICs, as well as within different populations in the same 
country. Patients with chronic diseases in LMICs face  several 
 challenges in accessing medicines. These include poor 
availability and affordability of the medicines, inadequate 
public spending on health, high household out-of-pocket 
expenditure, and inadequate health insurance coverage.65 
Chronic disease medications are even more burdened by limi-
tations in access as significant differences in the availability 
of medicines for chronic diseases versus acute diseases in 
both public and private sector settings in LMICs have been 
reported (36% vs 53.5% in the public sector and 54.7% vs 
66.2% in the private sector).66
Cost is a significant barrier to access medicines for 
patients with diabetes in LMICS. In these populations, health 
care expenditure is mostly out-of-pocket, further propagat-
ing the vicious cycle of poverty as medicines consume large 
portions of household incomes. In Mali, for instance, care for 
a person with diabetes consumes nearly 70% of a family’s 
income.67 In Nigeria, a monthly mean cost of $33.10 for a 
person with diabetes was reported, which corresponds to 29% 
of the total monthly income of an individual on minimum 
wage.68 Because of these stark realities, many patients opt to 
try to cope with diabetes without medications and suffer many 
preventable complications. In particular, lack of insulin in 
people with insulin-requiring diabetes can lead to DKA, and 
eventually death. Some sub-Saharan African countries have 
reported that up to 50% of deaths in patients with insulin-
requiring diabetes were from DKA.69 Although programs like 
the IDF’s Life for a Child have helped address the insulin 
needs of thousands of children with type 1  diabetes, large 
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Figure 5 Diabetes management protocols.
Notes: Partners in health guidelines for type 2 diabetes management in low- and middle-income countries. Adapted from Kidder A, Kwan G, Cancedda C, Bukhman G. 
Diabetes. In: Bukhman G, Kidder A, editors. The PIH guide to chronic care integration for endemic non-communicable diseases. Rwanda ed. Boston, MA: Partners in Health; 
2011:153–187. Copyright © 2011 Partners In Health. All rights reserved under International and Pan-American Copyright Conventions.
Abbreviations: NCD, noncommunicable disease; NS, normal saline; SC, subcutaneous. 
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disparities exist in reliability and availability for insulin 
throughout sub-Saharan Africa. Past analyses have found 
that type 1 patients in Democratic Republic of Congo had 
access to insulin <25% of the time.70 Similar studies from 
Tanzania found that different types of insulin were only avail-
able in public sector facilities 8%–17% of the time, and a 
separate analysis found that at least one version of insulin was 
available only 34% of the time.71,72 In one of the few formal 
published evaluations using the Rapid Assessment Protocol 
for Insulin Access (RAPIA) evaluations in Mozambique, 
supply was consistently available at only 20% of the hospital 
facilities and at none of the health centers.73 Even when this 
life-saving medication is available, the high prices of insulin 
and limited availability of reliable generics remain out of 
reach for most. In addition, reliable and affordable access 
to insulin syringes, as well as blood glucose testing devices 
and test-strips that are essential for optimal glycemic control 
pose a challenge to many people with diabetes.67,73
Rational selection of medicines
Appropriate selection of medicines can signif icantly 
improve coverage within limited budgets. The WHO pub-
lishes a Model List of Essential Medicines that provides a 
 framework from which other countries can develop their 
National Essential Medicines List (NEML). NEMLs are 
important in ensuring countries appropriately prioritize 
their expenditure on evidence-based, cost-effective medi-
cines.74 However, only 38% of 15 sub-Saharan countries 
had updated their NEML in the past 5 years.64 The WHO 
Model List of Essential Medicines includes both short-
acting and long-acting insulin formulations, as well as 
oral hypoglycemic agents.52 An evaluation of NEMLs in 
2014 reported that although these medicines were present 
in the NEMLs of almost all of the 32 LMICs included in 
the survey, they were still not adequately available and 
affordable in these countries, suggesting poor implementa-
tion of the NEMLs.74
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Use of generic medicines
Generic medicines increase competition and have been shown 
to significantly reduce the cost of essential medicines. For 
example, the introduction of generic oral hypoglycemic 
agents has reduced their cost to <$1 per month. Although 
oral hypoglycemic agents have enjoyed significant cost 
reductions over the last few years as a result of the introduc-
tion of their generic counterparts, this has not been the case 
with insulin which has consistently remained unaffordable 
to most people with diabetes in sub-Saharan Africa. Among 
the barriers limiting the use of generic insulin are legal 
barriers and patent restrictions such as the Trade Related 
Aspects of Intellectual Property Rights agreement. Most of 
the oral hypoglycemic medicines on the WHO Model List 
are off-patent and are therefore not adversely affected by the 
international property rights laws. Although human insulin 
is also off-patent, it is still unavailable in many LMICs. The 
pharmaceutical industry has been criticized for incremental 
improvements that increase the patent life of insulin, leading 
to what is now being termed as “evergreening.” As a result 
of these tactics, insulin has remained largely unaffordable in 
many countries over the years. However, data on the quality 
of the insulin manufactured in these countries has not been 
reliably ascertained. Generic medicines have to undergo 
bioequivalence testing to ensure that they conform to safety 
and efficacy standards similar to the innovator brands. The 
majority of LMICs do not have the capacity to carry out their 
own independent quality assurance tests on generic medicines 
and have to rely on HICs or the WHO.75,76 The WHO has a 
prequalification program that assures the quality and safety 
of generics such as medicines for HIV and malaria. However, 
suppliers of insulin are yet to be prequalified as the WHO 
cites lack of funds, instead focusing on the more pressing 
infectious diseases.76
Path to progress
Providing access to medicines is one of the cornerstones of 
ensuring optimal care for people with diabetes in sub-Saharan 
Africa. However, this will require coordinated efforts from 
all stakeholders along the continuum of care. Governments 
have a duty and responsibility to ensure that medicines 
are available and affordable to all their citizens. However, 
poor financing and fragmented supply chain systems have 
resulted in chronic deficiencies of essential medicines in 
sub-Saharan Africa, especially within the public sector. 
Addressing challenges with selection and pricing of drugs 
during procurement will ensure that governments get the 
best value for money and significantly increase affordability 
of medicines to the end users. Fortunately, the Sustainable 
Development Goals have recently included a specific target of 
ensuring access to medicines and pursuing research on NCDs 
in LMICs which will hopefully increase the availability of 
effective diabetes medications.77
Furthermore, to maximize the benefits of these medica-
tions, the entire health care infrastructure must be strength-
ened and redesigned to ensure that these medicines reach 
patients and are appropriately monitored to maximize benefits 
and minimize risks.
Systems of care
Much like other chronic diseases, diabetes is a disease whose 
management requires significant coordination between many 
different aspects of the health care delivery system.1 This 
requirement for coordination has been consistently found 
in all settings, regardless of income, and is especially pro-
nounced for diabetes considering the multiple organ systems 
that diabetes affects. However, significant challenges are 
faced in settings where limited human resources for health 
combine to disrupt efforts to create cohesive and adequately 
staffed care delivery systems.78
The limited organization complicates care as patients face 
considerable difficulty transitioning between initial screen-
ing, outpatient care, inpatient care, and self-management. As 
seen in Table 1, the key overarching challenges within each 
of these nodes of the health care system are illustrated with 
the poor resultant outcomes of this fragmented approach.
Screening/prevention
In terms of screening, sub-Saharan Africa is plagued with 
the lowest rates of diagnosis in the world.2 With the limited 
emphasis on preventative medicine compared with the typi-
cal focus on acute health care needs found in most LMICs, 
patients are rarely presented with opportunities for the early 
diagnosis of diabetes before symptoms and life-threatening 
complications set in. Even when symptoms set in, the 
relatively low level of awareness among providers and the 
community combined with the aforementioned limitations 
in testing supplies prevents patients from getting the early 
intervention they desperately need. Pilot efforts to combat 
this have focused on screening high-risk populations that fit 
the determinants of disease identified in HICs.79 Although 
this strategy has been effective for urban populations, its 
applicability to rural populations is limited as the dynamics 
of disease are dramatically different and the typical empha-
sis on lifestyle modifications for populations that already 
engage in highly active lifestyles with limited dietary options 
have limited resonance with the population in question.43 
Although most diabetes prevention and management efforts 
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typically focus on caloric restriction, studies from rural set-
tings in sub-Saharan Africa have found that 30% of diabetes 
patients in a rural, public sector clinic report some level of 
food insecurity.80 It is because of atypical characteristics like 
this and the higher prevalence of understudied variants that 
rural populations require distinct education, screening, and 
management strategies.  
Outpatient care
Although there are clear deficiencies within the current 
screening and prevention strategies utilized in sub-Saharan 
Africa, even more pressing needs exist within the avail-
ability of reliable and impactful outpatient care that screen-
positive patients would depend on. With many limitations 
in policy focus and attention given to NCDs like diabetes, 
the poor quality of outpatient care for diabetes serves as a 
microcosm for all other NCDs in sub-Saharan Africa. The 
current state of diabetes care is an almost inevitable conse-
quence of the many gaps in care described throughout this 
review. In addressing the key gaps in outpatient care, several 
fundamental aspects must be considered. Prior to the rapid 
rise in diabetes seen over the last two decades, diabetes was 
a relatively rare  condition in rural sub-Saharan Africa and a 
somewhat uncommon condition even in urban settings.3 At 
the same time, communicable diseases were gaining con-
siderable attention because of their disproportionate toll on 
sub-Saharan African societies. Because of these dynamics, 
the emphasis and focus on training health care providers 
about diabetes was often sacrificed in the interest of promot-
ing education for heavily funded diseases including TB, HIV, 
and malaria. This has created a vacuum where providers and 
ministries of health have become experts on management and 
creation of infrastructure to handle the acute complications of 
 communicable diseases but have de-emphasized the creation 
of infrastructure designed to handle the chronic disease man-
agement needs of patients. Although there are many ongoing 
efforts focused on expanding the benefits of HIV health care 
infrastructure to other chronic diseases, these efforts are still 
largely limited to small pilots that have not been scaled.81–84
The disparity in outpatient care is further complicated by 
the dichotomy seen between population dense urban areas that 
attract the majority of diabetes-trained providers compared 
with rural areas that have only limited health care worker 
resources to handle a much larger population scattered over 
a vast terrain.63 This drastic disparity between rural and urban 
settings is illustrated in all facets of outpatient diabetes man-
agement with patients from urban settings typically having 
much greater access to specialized care for diabetes-related 
complications, diabetes-specific laboratory tests, and newer 
medications. Urban settings also tend to have a higher pre-
dominance of patients with the ability to pay higher private 
sector prices. These factors have created a situation where 
infrastructure for tests like the glycosylated hemoglobin 
(HbA1c) are readily available in urban private sector facilities 
while being absent in rural areas that largely rely on public sec-
tor health care delivery. For example, in Kenya, the disparity in 
pricing and uptake can be seen where private sector providers 
charge ~US$25 per HbA1c test compared with US$10 in the 
public sector. Despite the much lower charges in the public 
sector, <20% of patients perform this vital test.85,86
Instead, most patients in the public sector rely on a single 
random blood glucose (if available) on the day of their visit 
to determine the status of their diabetes while visiting health 
care providers. All these factors have left patients with 
diabetes with a very bleak picture as they try to prevent the 
inevitable, insidious complications of diabetes. Even when 
patients do screen positive for diabetes in the community, 
there is considerable reluctance with accessing care at public 
sector facilities with findings from rural sub-Saharan Afri-
can settings, illustrating that <25% return for confirmation 
despite phone-based follow-up and reminders.7 In further 
qualitative analyses of barriers to linkage to care for NCD 
Table 1 Overarching challenges and outcomes found in different levels of the health care system in sub-Saharan Africa (SSA)
Screening/prevention Outpatient care Inpatient care Self-management Outcomes
•	 Routine screening 
largely unavailable
•	 Limited access to 
HbAlc and other vital 
laboratory tests
•	 Inadequate 
infrastructure to manage 
hyperglycemic crises
•	 Limited affordability and 
infrastructure to support home 
glucose monitoring
•	 Highest mortality rate 
from diabetes in the 
world
•	 When screening is 
conducted, less than 
30% link to care in the 
public sector
•	 Unacceptably high 
mortality rates from 
hyperglycemic crises
•	 Many public sector facilities 
require patients to come to 
facilities twice a day to receive 
direct insulin administration
•	 Largest undiagnosed 
population of diabetes 
in the world with 
over 62% remaining 
undiagnosed
•	 Limited emphasis on 
prevention and unclear 
prevention strategy in 
rural settings
•	 High diabetes-related 
complication rates
•	 Limited access to 
specialized management 
of complications
•	 Limited availability of peer 
support, educational programs 
or peer-based care
•	 SSA has the greatest 
anticipated increase in 
diabetes prevalence
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patients, patients frequently mention the financial challenges 
in addressing NCDs, poor quality of public sector facilities, 
feeling like they are a burden to the family, and the distant 
travel required to reach the facilities.87
Similar to HIV patients in sub-Saharan Africa, prior to 
the provision of highly active antiretroviral therapy, diabetes 
patients are left with few outpatient management options 
as the current costs of care are exorbitantly high in relation 
to their earnings with high-quality access being reserved 
for the few patients who can afford it. This has created a 
dynamic where diabetes patients frequently rely on inpatient 
care to provide short-term fixes for their acute complica-
tions or rely on facilities to serve as their final resting place 
as their health care needs surpass the currently available 
infrastructure. The unfortunate reality that inpatient provid-
ers face in managing diabetes is eerily reminiscent of the 
situation faced when trying to cope with the preventable 
mortalities faced during the height of the HIV epidemic in 
sub-Saharan Africa.
Inpatient care
Although inpatient care is typically intended to address the 
short-term, acute complications of diabetes, it is commonly 
used to fill in the gaps in outpatient care. With the frequent 
medication stock-outs, difficulties with accessing insulin, and 
suboptimally managed and diagnosed infectious diseases, 
patients are often prone to frequent bouts of hyperglycemia 
requiring inpatient admission and insulin administration.88,89 
Unfortunately, this reliance on ill-equipped inpatient 
facilities leads to unacceptably high levels of mortality from 
the different manifestations of hyperglycemia. For example, 
past studies in sub-Saharan Africa have found high mortal-
ity rates of 25%–33% for patients presenting to the hospital 
with DKA. This is in contrast to the much lower mortality 
rates of 2%–5% found for DKA in HIC inpatient settings. 
The risk of death from hyperosmolar non-ketotic coma is 
even more concerning as past studies in South Africa found a 
44% mortality rate within an inpatient setting compared with 
~15% from data obtained from HICs over 20 years ago.43,90–92
Although these mortality rates for inpatient care are 
quite concerning, this only represents the small fraction of 
the population of patients who are even able to make it to an 
inpatient facility for the management of their acute diabetes 
complications. The lack of access to high-quality diabetes 
care combined with the suboptimal performance of  hospitals 
contributes to the alarmingly high early mortality sub-
Saharan African patients face with 76% of diabetes-related 
death occurring before the age of 60.2 
In addition to reliance on inpatient care for management of 
acute complications, the inevitable consequences of  diabetes 
on other organ systems stretches limited resources even 
further. With the high rates of diabetes-related kidney injury, 
a large proportion of patients with diabetes who are able to 
survive beyond the age of 60 years eventually require dialysis. 
Despite the relatively low prevalence of diabetes found in 
sub-Saharan Africa, diabetes was one of the main drivers of 
end-stage renal disease even in data obtained over 15 years 
ago.92 More than one third of patients receiving care within 
dialysis units had diabetes.43,94 The importance of addressing 
kidney-related complications cannot be understated, as it is 
estimated that 50% of the diabetes-related mortality is attrib-
uted to renal disease even in patients with type 1 diabetes.43 
With the dramatically higher rates of kidney dysfunction, 
the availability of dialysis units is quickly outpaced by the 
numbers of patients with diabetes-related end-stage renal 
disease requiring long-term dialysis for survival. In addition 
to the reliance on inpatient care for complications associated 
with hyperglycemia, patients in sub-Saharan Africa often 
require hospitalizations for hypoglycemia. With the limited 
options for medications and unique pathophysiology of 
diabetes in sub-Saharan Africa, patients are often prescribed 
sulfonylureas and/or insulin. This has contributed to frequent 
bouts of hypoglycemia that have become an all too common 
cause of preventable inpatient admission and excess morbid-
ity and mortality. The limited provision of counseling with 
the prescription of these medications, combined with the 
high rates of food insecurity leads to a potentially lethal 
situation.  In order to combat this, strategies to combat the 
many preventable causes of inpatient admission must include 
a shift from continued reliance on limited health care worker 
resources toward care systems that equip patients with 
highly effective self-management strategies to independently 
address many of these preventable situations.
Self-management
With many aforementioned deficiencies in care provision, 
there has only been limited effort in building the structures 
necessary to promote safe and effective self-management 
strategies. Although self-monitored blood glucose (SMBG) 
has become a prerequisite component of care for patients 
with diabetes in HICs, especially those requiring insulin, this 
modality of care is largely inaccessible in sub-Saharan Africa. 
The relatively high cost, time intensive nature, high demands 
on limited health care worker resource, and coordination of 
care required for SMBG have resulted in lower prioritization 
of this proven care strategy. Despite several pilot  investigations 
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in sub-Saharan Africa demonstrating the feasibility and >30% 
reductions in the HbA1c after just 3 months of SMBG with 
phone-based support, provision of this service is still slow to 
reach even private sector settings.29,95,96 Although wide-scale 
provision of this service would undoubtedly improve care, 
a more cost-effective strategy that incorporates many of the 
task shifting care strategies utilized with other chronic dis-
eases like HIV could lead to dramatic, sustainable impact for 
diabetes care. For example, the incorporation of community 
health workers into the HIV delivery system has reduced 
the overarching cost of care delivery while simultaneously 
improving patient outcomes. This transition to community 
health workers could have similar benefits for diabetes.97,98
Pilot strategies including the provision of contextualized 
diabetes awareness materials utilizing conversation maps to 
provide group-based diabetes education have demonstrated 
effectiveness, however, are still relegated to relatively small-
scale impact as they have not yet been broadly scaled up.99,100
Other strategies have succeeded in creating sustainable 
and impactful care delivery by linking group-based micro-
finance to portable group-based care delivery for NCDs.101 
Although most of these pilots have been limited to very 
small-scale implementations, it is clear that a successful 
long-term solution requires consideration of the multifaceted 
challenges that patients in sub-Saharan Africa face in trying 
to access and pay for higher quality care.
Path to progress
With many deficits in various levels of the health care system, 
there needs to be a significant investment in both the public 
and private sectors to raise the level of care patients can rely 
on while seeking desperately needed services. However, to 
ensure long-term sustainability of these services, large-scale 
integration with other well developed health care infrastruc-
ture (ie, HIV), novel payment strategies, and care delivery 
methods must be considered to promote the implementation 
of more patient-centric services that meet the demands and 
unique needs of patients with diabetes in sub-Saharan Africa. 
Discussion/conclusion
With the marked uniqueness of diabetes in sub-Saharan 
Africa in all aspects of the disease, it is clear that there is 
much needed effort to pursue sub-Saharan Africa-specific 
diabetes research rather than the current approach of relying 
on lessons learned from HICs to a dissimilar disease process, 
policy landscape, and markedly different health care system. 
Although there are many unanswered questions surround-
ing diabetes in sub-Saharan Africa, it is clear that there are 
many solvable immediate needs that need to be addressed 
to prevent the unacceptably high levels of excess morbidity 
and mortality that the patients are currently experiencing.  
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